



PC-3



LNCaP



S2 Changes in mitochondrial membrane potential (MMP) in PC-3 and LNCaP cells treated with LA-12/cisplatin and TRAIL. Percentage of PC-3 and LNCaP cells with decreased MMP (TMRE assay, flow cytometry) following pretreatment (24 h) with LA-12 (0.5/2.5 μ M) or cisplatin (10/5 μ M) and treatment (4 h) with TRAIL (5/20 ng/ml), respectively. Results are means + S.E.M. of 3 independent experiments. Statistical significance ($P < 0.05$, * vs. control, † vs. TRAIL, □ vs. appropriate platinum drug).